Real world experience with antiphospholipid antibody tests: how stable are results over time?
OBJECTIVE
To determine the stability and the degree of variation of antiphospholipid antibody (aPL) results over time in a large cohort of well evaluated aPL positive patients; and to analyse factors contributing to aPL variation and the validity of aPL in a real world setting in which aPL tests are done in multiple laboratories.


METHODS
The clinical characteristics, drug treatment, and 1652 data points for lupus anticoagulant (LA), anticardiolipin antibodies (aCL), and anti-beta2 glycoprotein I antibodies (anti-beta2GPI) were examined in 204 aPL positive patients; 81 of these met the Sapporo criteria for antiphospholipid syndrome (APS) and 123 were asymptomatic bearers of aPL.


RESULTS
87% of initially positive LA results, 88% of initially negative to low positive aCL results, 75% of initially moderate to high positive aCL results, 96% of initially negative to low positive anti-beta2GPI results, and 76% of initially moderate to high positive anti-beta2GPI results subsequently remained in the same range regardless of the laboratory performing the test. Aspirin, warfarin, and hydroxychloroquine use did not differ among patients whose aCL titres significantly decreased or increased or remained stable. On same day specimens, the consistency of aCL results among suppliers ranged from 64% to 88% and the correlation ranged from 0.5 to 0.8. Agreement was moderate for aCL IgG and aCL IgM; however, for aCL IgA agreement was marginal.


CONCLUSIONS
aPL results remained stable for at least three quarters of subsequent tests, regardless of the laboratory performing the test; the small amount of variation that occurred did not appear to be caused by aspirin, warfarin, or hydroxychloroquine use.
Erkan
D
D
Department of Rheumatology, Hospital for Special Surgery, Weill Medical College of Cornell University, 535 E70th Street, New York, NY 10021, USA. derkan@pol.net
Derksen
W J M
WJ
Kaplan
V
V
Sammaritano
L
L
Pierangeli
S S
SS
Roubey
R
R
Lockshin
M D
MD
D000328:Adult; D017153:Antibodies, Anticardiolipin / Q000097:blood; D017152:Antibodies, Antiphospholipid / Q000097:blood*; D016736:Antiphospholipid Syndrome / Q000175:diagnosis*; D015415:Biomarkers / Q000097:blood; D015331:Cohort Studies; D005260:Female; D006023:Glycoproteins / Q000276:immunology; D006801:Humans; D016682:Lupus Coagulation Inhibitor / Q000097:blood; D008297:Male; D008875:Middle Aged; D015203:Reproducibility of Results; D053482:beta 2-Glycoprotein I
D017153:Antibodies, Anticardiolipin; D017152:Antibodies, Antiphospholipid; D015415:Biomarkers; D006023:Glycoproteins; D016682:Lupus Coagulation Inhibitor; D053482:beta 2-Glycoprotein I
Pathology. 2004 Apr;36(2):174-81
15203755
Arthritis Rheum. 1999 Jul;42(7):1309-11
10403256
Thromb Res. 2004;114(5-6):597-601
15507297
Am J Med. 1988 Nov;85(5):602-8
3189362
Am J Obstet Gynecol. 1989 Feb;160(2):439-43
2916633
J Rheumatol. 2000 Dec;27(12):2833-7
11128672
Thromb Haemost. 2002 Jul;88(1):66-73
12152681
Blood. 2003 Mar 1;101(5):1827-32
12393574
Thromb Res. 2003;111(1-2):29-32
14644075
Rheumatology (Oxford). 2004 Feb;43(2):181-5
14585922
Am J Clin Pathol. 1990 Oct;94(4):476-84
2220676
Ann Rheum Dis. 1992 Mar;51(3):353-7
1575581
Ann Intern Med. 1992 Dec 15;117(12):997-1002
1443986
Thromb Haemost. 1994 Aug;72(2):209-13
7831653
Thromb Haemost. 1995 Oct;74(4):1185-90
8560433
Br J Haematol. 1997 Mar;96(3):447-50
9054646
Haematologica. 1997 Jan-Feb;82(1):101-5
9107095
Stroke. 1997 Sep;28(9):1660-5
9303006
Thromb Res. 2004;114(5-6):559-71
15507292